|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:ATCCode
|
J05AG05
|
|
gptkbp:bioavailability
|
44%
|
|
gptkbp:CASNumber
|
500287-72-9
|
|
gptkbp:contraindication
|
gptkb:rifampicin
gptkb:phenytoin
gptkb:carbamazepine
gptkb:St._John's_Wort
|
|
gptkbp:halfLife
|
45 hours
|
|
gptkbp:hasMolecularFormula
|
C16H19N3O3S
|
|
gptkbp:hasSMILES
|
CC1=CN(C2=CC=CC=C2N=C1)C3=NC(=CC(=C3)C#N)S(=O)(=O)N
|
|
gptkbp:hasUNII
|
N8Z460B5D0
|
|
gptkbp:isAntiviral
|
true
|
|
gptkbp:isNonNucleosideReverseTranscriptaseInhibitor
|
true
|
|
gptkbp:isPregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketedAs
|
gptkb:Edurant
|
|
gptkbp:metabolism
|
gptkb:CYP3A
|
|
gptkbp:molecularWeight
|
333.41
|
|
gptkbp:proteinBinding
|
99.7%
|
|
gptkbp:PubChem_CID
|
gptkb:DB06287
gptkb:CHEMBL164522
6451164
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:Rilpivirine
|
|
gptkbp:target
|
HIV-1 reverse transcriptase
|
|
gptkbp:usedFor
|
treatment of HIV-1 infection
|
|
gptkbp:bfsParent
|
gptkb:temsirolimus
gptkb:reslizumab
gptkb:Torisel
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB06287
|